This study is for adults with advanced germ cell, endometrial, or ovarian cancers that have not responded to previous treatments. You may be able to join if standard treatments are no longer working or are not suitable for you. The study is testing different doses of BI 3820768, a treatment that may help your immune system fight cancer. This is the first time BI 3820768 is being tested in people. The main goal is to find a dose that is well-tolerated and may shrink tumors. The study will also look at any side effects. BI 3820768 will be given by injection, and there are two different ways it can be given depending on when you join the study.

Study design

This is an interventional study planning to enroll 187 participants. It is testing increasing doses of BI 3820768.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for treatment-emergent adverse events (side effects) and dose-limiting toxicities for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.